WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 581490
Description: α-Pyrrolidinobutiophenone (α-PBP) is discontinued (DEA controlled substance). It is a stimulant compound. It can be thought of as the homologue lying between the two better known drugs α-PPP and α-PVP.
MedKoo Cat#: 581490
Chemical Formula: C14H19NO
Exact Mass: 217.1467
Molecular Weight: 217.31
Elemental Analysis: C, 77.38; H, 8.81; N, 6.45; O, 7.36
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: alpha-PBP; alpha-Pyrrolidinobutiophenone;
IUPAC/Chemical Name: 1-Phenyl-2-(pyrrolidin-1-yl)butan-1-one
InChi Key: GSESDIFGJCCBHN-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H19NO/c1-2-13(15-10-6-7-11-15)14(16)12-8-4-3-5-9-12/h3-5,8-9,13H,2,6-7,10-11H2,1H3
SMILES Code: CCC(N1CCCC1)C(C2=CC=CC=C2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 217.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Franzén L, Bäckberg M, Beck O, Helander A. Acute Intoxications Involving α-Pyrrolidinobutiophenone (α-PBP): Results from the Swedish STRIDA Project. J Med Toxicol. 2018 Jun 19. doi: 10.1007/s13181-018-0668-2. [Epub ahead of print] PubMed PMID: 29923027.
2: Manier SK, Richter LHJ, Schäper J, Maurer HH, Meyer MR. Different in vitro and in vivo tools for elucidating the human metabolism of alpha-cathinone-derived drugs of abuse. Drug Test Anal. 2018 Jan 4. doi: 10.1002/dta.2355. [Epub ahead of print] PubMed PMID: 29314710.
3: Beck O, Bäckberg M, Signell P, Helander A. Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. Clin Toxicol (Phila). 2018 Apr;56(4):256-263. doi: 10.1080/15563650.2017.1370097. Epub 2017 Sep 12. PubMed PMID: 28895757.
4: Drug Enforcement Administration, Department of Justice. Schedules of Controlled Substances: Placement of 10 Synthetic Cathinones Into Schedule I. Final rule. Fed Regist. 2017 Mar 1;82(39):12171-7. PubMed PMID: 28355044.
5: Drug Enforcement Administration, Department of Justice. Schedules of Controlled Substances: Extension of Temporary Placement of 10 Synthetic Cathinones in Schedule I of the Controlled Substances Act. Final order. Fed Regist. 2016 Mar 4;81(43):11429-31. PubMed PMID: 26964151.
6: Kolanos R, Sakloth F, Jain AD, Partilla JS, Baumann MH, Glennon RA. Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters. ACS Chem Neurosci. 2015 Oct 21;6(10):1726-31. doi: 10.1021/acschemneuro.5b00160. Epub 2015 Aug 11. PubMed PMID: 26217965; PubMed Central PMCID: PMC5349767.
7: Gatch MB, Dolan SB, Forster MJ. Comparative Behavioral Pharmacology of Three Pyrrolidine-Containing Synthetic Cathinone Derivatives. J Pharmacol Exp Ther. 2015 Aug;354(2):103-10. doi: 10.1124/jpet.115.223586. Epub 2015 May 21. PubMed PMID: 25998047; PubMed Central PMCID: PMC4518071.
8: Matsuta S, Shima N, Kamata H, Kakehashi H, Nakano S, Sasaki K, Kamata T, Nishioka H, Miki A, Katagi M, Zaitsu K, Sato T, Tsuchihashi H, Suzuki K. Metabolism of the designer drug α-pyrrolidinobutiophenone (α-PBP) in humans: identification and quantification of the phase I metabolites in urine. Forensic Sci Int. 2015 Apr;249:181-8. doi: 10.1016/j.forsciint.2015.02.004. Epub 2015 Feb 8. PubMed PMID: 25703013.
9: Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Suzuki O, Watanabe K. Postmortem distribution of α-pyrrolidinobutiophenone in body fluids and solid tissues of a human cadaver. Leg Med (Tokyo). 2014 Sep;16(5):241-6. doi: 10.1016/j.legalmed.2014.05.001. Epub 2014 May 19. PubMed PMID: 24889409.
10: Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of 10 synthetic cathinones into Schedule I. Final order. Fed Regist. 2014 Mar 7;79(45):12938-43. PubMed PMID: 24611212.
11: Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH. Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology. 2014 Dec;87:206-13. doi: 10.1016/j.neuropharm.2014.02.016. Epub 2014 Mar 2. PubMed PMID: 24594476; PubMed Central PMCID: PMC4152390.